Meetings - The ASCO Post

Despite advances in targeted therapies for hematologic malignancies, drug resistance and persistent side effects continue to challenge clinicians and limit patient outcomes, underscoring the urgent ne...

Leukemia

By Caroline Helwick / August 25, 2024 / 2024 Pan Pacific Lymphoma Conference

What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?

Is the optimal first-line treatment of chronic lymphocytic leukemia (CLL) monotherapy with a Bruton’s tyrosine kinase (BTK) inhibitor or some combination regimen? This clinical question was explored b...

Lymphoma

By Caroline Helwick / September 10, 2024 / 2024 Pan Pacific Lymphoma Conference

Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?

Most patients with extranodal marginal zone lymphoma (MZL) are overtreated, according to Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and Institute of Oncology Research in Bel...

2024 Pan Pacific Lymphoma Conference

BTK Degraders and CELMoDs: Novel Mechanisms Overcoming Resistance in Hematologic Malignancies

What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?

Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma

Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis Monitoring and Treatment

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer